Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Creabilis SA

Division of Sienna Biopharmaceuticals Inc.
www.creabilis-sa.com

Latest From Creabilis SA

Sienna CEO: IPO Investors Drawn By Experienced Dermatology Team

Sienna Biopharmaceuticals went from Series A to IPO in 15 months, selling investors on its executive team experienced in the development and commercialization of dermatology and aesthetic products.

Financing Business Strategies

Finance Watch: OncoMed Cuts Costs To Conserve Capital While Public, Private Peers Raise Cash

OncoMed lays off half its employees after a series of recent clinical setbacks. Meanwhile, six public companies raise $1.64bn in $100m-plus follow-on and debt offerings, SV Health Investors closed a $400m venture capital fund and eight therapeutics firms grabbed $247.5m in VC cash.

Financing Business Strategies

Deals Shaping the Medical Industry, January 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.

Deals BioPharmaceutical

Deal Watch: Focus Placed On Psoriasis With Recent Purdue, Sienna Deals

Purdue will partner with Exicure to develop psoriasis therapies using the latter’s Spherical Nucleic Acid platform, while Sienna buys Creabilis to advance its psoriasis candidate to Phase III. Meanwhile, one focus of the Almirall/Nuevolution tie-up will be psoriatic arthritis.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Inflammation
  • Alias(es)
  • Creabilis Therapeutics SRL
  • Creabilis Ltd.
  • Creabilis Therapeutics SPA
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Italy
  • Parent & Subsidiaries
  • Sienna Biopharmaceuticals Inc.
  • Senior Management
  • Eliot Forster, CEO
    Silvio Traversa, PhD, CSO
    David Roblin, MD, CMO
    James Sandy, SVP, Head, Dev.
    Alex Leech, VP, Head, Fin. & Ops.
    Simon Russell, PhD, CBO
  • Contact Info
  • Creabilis SA
    Phone: (39) 125 53543
    Bioindustry Park del Canavese
    Via Ribes 5
    Colleretto Giacosa, 10010
    Italy
Advertisement
Advertisement
UsernamePublicRestriction

Register